Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Clin Chim Acta. 2012 Dec 24;414:93-100. doi: 10.1016/j.cca.2012.08.018. Epub 2012 Aug 25.
We compared the diagnostic utilities of CYFRA 21-1, nuclear matrix protein-22 (NMP22), urinary bladder cancer antigen (UBC), and fibrin/fibrinogen degradation products (FDP) for detecting urinary bladder cancer.
We assayed CYFRA 21-1, NMP22, UBC and FDP from urine samples for 250 subjects. Among them, 54 were diagnosed as bladder cancer, and the remaining 196, which consisted of healthy individuals and patients with hematuria, inflammation/infection, or benign prostate hyperplasia, were assigned to the control group.
Urinary levels of all 4 markers were higher in the bladder cancer group than the control group. The areas under the receiver operating characteristic curves (ROC-AUCs) of CYFRA 21-1, NMP22, UBC and FDP, corrected with urine creatinine concentrations, were 0.90, 0.89, 0.80 and 0.77, respectively, for discriminating bladder cancer from controls. The ROC-AUCs for the combinations of the markers were not significantly higher than those with CYFRA 21-1 or NMP22. NMP22 was the only independent variable for predicting bladder cancer among the four markers in the multivariate analysis.
All 4 tumor biomarkers exhibited diagnostic utility for predicting bladder cancer. Among them, CYFRA 21-1 and NMP22 were the most effective at predicting bladder cancer.
我们比较了细胞角蛋白 21-1（CYFRA 21-1）、核基质蛋白-22（NMP22）、尿膀胱癌抗原（UBC）和纤维蛋白/纤维蛋白原降解产物（FDP）在检测膀胱癌方面的诊断效用。
我们对 250 例患者的尿液样本进行了 CYFRA 21-1、NMP22、UBC 和 FDP 的检测。其中，54 例被诊断为膀胱癌，其余 196 例由健康个体以及血尿、炎症/感染或良性前列腺增生患者组成，被分配到对照组。
膀胱癌组患者尿液中所有 4 种标志物的水平均高于对照组。经尿肌酐浓度校正后，CYFRA 21-1、NMP22、UBC 和 FDP 的受试者工作特征曲线（ROC-AUC）面积分别为 0.90、0.89、0.80 和 0.77，用于区分膀胱癌和对照组。与 CYFRA 21-1 或 NMP22 相比，标志物组合的 ROC-AUC 并没有显著提高。在多变量分析中，NMP22 是这 4 种标志物中唯一能预测膀胱癌的独立变量。
所有 4 种肿瘤标志物均具有预测膀胱癌的诊断效用。其中，CYFRA 21-1 和 NMP22 对预测膀胱癌最有效。
